CEO Executive AssistantPatient services - the constellation of programs that help patients afford, access, and adhere to pharmaceutical therapies - has grown from a peripheral commercial function to a strategic imperative for pharmaceutical companies. For specialty and rare disease products where annual therapy costs can reach hundreds of thousands of dollars, patient services programs are often the difference between a patient receiving treatment and being denied access. For CEOs of pharmaceutical companies, the ethical, commercial, and operational dimensions of patient services create a distinctive delegation challenge.
This guide examines how pharma CEOs can structure delegation of patient services operations while maintaining appropriate strategic oversight of programs that are simultaneously business-critical and directly consequential to patient lives.
The Strategic Importance of Patient Services
Patient services sits at the intersection of commercial strategy, payer relations, patient advocacy, and corporate social responsibility. The programs that fall under patient services - including copay assistance, patient assistance programs (PAP), specialty pharmacy coordination, hub services, nursing support, and adherence programs - affect both commercial outcomes (patient start rates, persistence, market access) and patient outcomes (whether patients can access and successfully use a therapy).
Pharma CEOs are increasingly expected to articulate a patient access philosophy that goes beyond commercial rationale. Investors, patient advocacy organizations, policymakers, and the public all have views about how pharmaceutical companies should balance profitability and access. The CEO must set this philosophy and ensure it is reflected in patient services program design and execution.
At the same time, patient services operations are highly specialized, technologically intensive, and operationally complex. Copay card programs, specialty pharmacy onboarding, hub services call center management, and PAP administration require dedicated operational expertise that belongs to patient services leadership, not the CEO.
Harvard Business Review research on effective delegation underscores the importance of distinguishing strategic oversight (CEO-level) from operational execution (delegated) - a distinction that is particularly important in patient services, where the ethical weight of the function can tempt CEOs to over-involve themselves in operational details.
The Delegation Framework for Patient Services
Hub Services and Patient Onboarding
Hub services programs - centralized patient support platforms that coordinate specialty pharmacy enrollment, prior authorization support, insurance verification, and nurse case management - are the operational backbone of specialty pharmaceutical commercialization. These programs are complex to design and intensive to operate.
What to delegate:
- Hub vendor selection and contract management
- Hub performance monitoring and operational oversight
- Patient intake and enrollment process design and optimization
- Prior authorization support operations
- Benefits investigation and insurance verification management
- Specialty pharmacy onboarding coordination
To whom: VP of Patient Services or Head of Patient Access, working in coordination with market access and commercial leadership.
What the CEO retains: Strategic decisions about hub services program scope and investment level, CEO-level relationships with specialty pharmacy partners, and decisions about program design features that affect patient access policy (e.g., whether to support patients in Medicare Part D gap).
Copay Assistance Programs
Copay assistance programs are a significant commercial investment and a highly visible patient access mechanism. They are also subject to intense regulatory scrutiny, particularly regarding eligibility criteria, OIG compliance, and coordination with government-funded insurance programs.
What to delegate:
- Copay card program design and vendor management
- Copay card redemption monitoring and analytics
- OIG compliance program management for copay programs
- Patient assistance program eligibility determination and administration
- Foundation referral programs for government-insured patients
To whom: Head of Patient Services or Market Access Director, with legal and compliance support.
What the CEO retains: Strategic decisions about program structure that carry compliance or reputational risk, decisions about expanding or restricting program eligibility that significantly affect patient access, and investor-facing communication about patient access investments.
Patient Support and Adherence Programs
Beyond onboarding and financial assistance, specialty pharmaceutical companies often provide ongoing patient support services including nursing case management, disease education, injection training, and digital adherence tools.
What to delegate:
- Nurse case management program operations
- Patient education material development and review
- Digital adherence tool and app management
- Patient support program vendor management
- Patient-reported outcome and satisfaction monitoring
To whom: VP of Patient Services or a dedicated VP of Patient Engagement.
What the CEO retains: Decisions about significant program investments in patient support that affect the commercial or access strategy, and patient advocacy engagement related to support program design.
Delegating Patient Advocacy Relations in the Context of Patient Services
Patient advocacy organizations play a significant role in shaping patient services expectations. They communicate patient access barriers to pharmaceutical companies, provide input on program design, and publicly evaluate companies on their access practices. The patient advocacy relationship has both an operational dimension (day-to-day engagement, program feedback, collaborative initiatives) and a strategic dimension (CEO-level relationship with advocacy organization leadership).
What to delegate:
- Day-to-day patient advocacy organization relationship management
- Patient advocacy advisory board coordination
- Grant and sponsorship program management for patient advocacy organizations
- Patient advocacy organization feedback integration into program design
To whom: Director of Patient Advocacy or VP of Patient Services.
What the CEO retains: Personal relationships with the CEOs and presidents of the most prominent disease-specific patient advocacy organizations in the company’s therapeutic areas, participation in major patient advocacy events as a visible organizational leader.
The pharma commercial strategy guide covers how patient services fits within the broader commercial delegation framework, including how to define the interface between patient services and market access functions.
Patient Services During Product Launch
Product launch is the most operationally critical period for patient services. Hub services, copay programs, and specialty pharmacy programs must be operational before the first prescription is written. Launch readiness for patient services requires dedicated program management and close coordination with commercial, regulatory, and medical affairs teams.
What the CEO oversees (not manages):
- Confirmation that patient services programs are launch-ready (monthly status review in the 6 months before launch)
- Resolution of any launch-blocking issues that require CEO authority or cross-functional decision-making
- External communication about patient access programs at launch
What is delegated:
- All operational launch readiness activities
- Hub build and testing
- Specialty pharmacy contract execution
- Patient services call center readiness
- Field reimbursement manager training
The pharma product launch guide covers the full delegation framework for launch activities, including the patient services readiness milestones that belong in the CEO’s launch monitoring dashboard.
Patient Services Compliance and Risk Management
Patient services programs operate in a complex and evolving compliance environment. OIG guidance, Anti-Kickback Statute considerations, HIPAA requirements, and state law variations all create compliance obligations. CEOs must ensure the compliance function is appropriately integrated with patient services operations without personally managing compliance activities.
What to delegate:
- Patient services compliance program design and monitoring
- Legal review of program design and marketing materials
- Compliance training for patient services staff and vendors
- Regulatory monitoring for patient services-related policy changes
To whom: Chief Compliance Officer and Legal team, working in close coordination with patient services leadership.
What the CEO retains: Awareness of material compliance risks in patient services programs, decisions about program design changes prompted by compliance risk, and escalation to the board audit committee for material compliance findings.
Metrics and Governance for Patient Services Delegation
Patient services leadership should report to the CEO through the following governance structure:
Monthly CEO dashboard: Patient start rates, copay program utilization and cost, hub services efficiency metrics (time-to-start, prior authorization success rates), patient satisfaction scores, and compliance incident summary.
Quarterly review: Deeper review with the VP of Patient Services covering program design issues, vendor performance, competitive landscape, and strategic access initiatives.
Annual review: Program cost vs. value analysis, strategic plan for patient services investment in the coming year, assessment of access barriers and program gaps.
Common Patient Services Delegation Failures
Patient story involvement. CEOs sometimes become personally involved in individual patient cases where access issues arise. While CEOs should be aware of access barriers at a systemic level, individual patient case management belongs to the patient services team. A policy that directs escalated patient cases to the patient services leadership - with escalation to the CEO only for cases involving media, litigation, or systemic policy failures - prevents individual cases from dominating CEO bandwidth.
Program cost micromanagement. Patient services programs are expensive, and CFOs sometimes push CEOs to reduce program investments. When the CEO personally reviews individual copay card transactions or sets per-patient cost targets for patient support programs, they are operating at the wrong level of granularity. The right CEO engagement is setting program investment strategy and ensuring the CFO and patient services teams have a shared view of program value.
Advocacy expectation management. Patient advocacy organizations sometimes escalate access requests directly to the CEO, bypassing patient services staff. A clear protocol - redirecting advocacy organization operational requests to the patient services team while preserving the CEO’s strategic advocacy relationships - prevents this from creating operational disruption.
Conclusion
Patient services is simultaneously one of the most ethically significant and operationally complex functions in a pharmaceutical company. CEOs who delegate operational management to capable patient services leaders - while maintaining strategic oversight of access philosophy, program investment, and advocacy relationships - create organizations that serve patients effectively and build the commercial and reputational foundation for long-term success.
The CEO’s patient services role is to set the access philosophy, ensure adequate program investment, hold the organization accountable for patient outcomes, and be the public face of the company’s commitment to patient access. The operational execution belongs to the patient services team.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.